Navigation Links
Penn biochemist receives NIH New Innovator's Award
Date:10/5/2007

PHILADELPHIA - James Shorter, PhD, Assistant Professor of Biochemistry and Biophysics at the University of Pennsylvania School of Medicine, has been named an inaugural recipient of the 2007 NIH Director's New Innovator Award. This highly prestigious award totals $1.5 million in direct costs over five years to each of 29 investigators, many of whom are in the early stages of their careers. More than 2,100 applications were received for this extremely competitive program.

As a key component of the National Institutes of Health (NIH) Roadmap for Medical Research, the New Innovator Award program supports exceptionally creative early-career scientists who take highly innovative approaches to major challenges in biomedical research. Shorter will develop biochemical methods to combat diseases caused by nerve degeneration, such as Parkinsons, Alzheimers, and Huntingtons.

Novel ideas and new investigators are essential ingredients for scientific progress, and the creative scientists we recognize with NIH Directors Pioneer Awards and NIH Directors New Innovator Awards are well-positioned to make significantand potentially transformativediscoveries in a variety of areas, said NIH Director Elias A. Zerhouni, MD.

This award is an honor, and a relief, in a way, to now be able to focus on my research in a significant way, says Shorter. Shorters lab seeks to understand how cells prevent, reverse, or even promote the formation of amyloid and prion fibers, extremely stable protein aggregates implicated in many neurodegenerative diseases. He aims to test his ideas using a panel of proteins that are implicated in human disease to search for potential cures for these disorders.

When amyloid fibers grow and divide they can be infectious, and are then termed prions. Prion and amyloid formation are associated with some of the most devastating neurodegenerative diseases confronting humans, including Alzheimer's disease, Parkinson's disease, and variant Creutzfeldt-Jacob disease.

Cells have evolved a sophisticated machinery to alleviate amyloid and prion aggregates, but these biological safeguards can be breached, especially as organisms age, and the consequences are often fatal. Working in a yeast model, Shorter and colleagues employ biochemistry and genetics to understand how the interactions between amyloid proteins and other proteins can be manipulated to avoid pathogenic outcomes and promote beneficial outcomes.

Shorter received his PhD from the Imperial Cancer Research Fund at University College London in 2000 and moved to Penn from the Whitehead Institute in Boston in April 2007.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related biology news :

1. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
2. UCR biochemist goes to Washington with high-protein corn
3. Precision biochemistry tracks DNA damage in fish
4. DuPonts first biologically derived polymer receives global recognition
5. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
6. Research on antibiotics receives historical recognition
7. Anthrax test, developed by army and CDC, receives FDA approval
8. Research team receives $7.5 million to study cassava
9. NJIT Presidential Award winner takes stem cell research another step
10. TGen awarded $7.1 million to accelerate brain disease research
11. Virtual microscopy project wins educational technology award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology: